Investigational drugs in dry eye disease

References

• The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international dry eye workShop (2007). Ocul Surf. 2007;5(2):97–107.
   Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international dry eye workShop (2007). Ocul Surf. 2007;5(2):75–92.
   PubMed Web of Science ®Google Scholar
• Cortina MS, Haydee EP. Docosahexaenoic acid, protectins and dry eye. Curr Opin Clin Nutr Metab Care. 2011;14:132–137.
   PubMed Web of Science ®Google Scholar
• Walter SD, Gronert K, McClellan AL, et al. ω-3 tear film lipids correlate with clinical measures of dry eye. Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2472–2478.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Petsoglou C, Gurbaxani A, et al. New agents for treating dry eye syndrome. Curr Allergy Asthma Rep. 2013;13:322–328.
   PubMed Web of Science ®Google Scholar
• Nebbioso M, Evangelista M, Librando A, et al. Iatrogenic dry eye disease: an eledoisin/carnitine and osmolyte drops study. Biomed Pharmacother. 2013;67:659–663.
   PubMed Web of Science ®Google Scholar
• Management and therapy of dry eye disease: report of the management and therapy subcommittee of the international dry eye workShop (2007). Ocul Surf. 2007;5(2):163–178.
   PubMed Web of Science ®Google Scholar
• Rand AL, Asbell PA. Nutritional supplements for dry eye syndrome. Curr Opin Ophthalmol. 2011;22:279–282.
   PubMed Web of Science ®Google Scholar
• Hom MM, Asbell P, Barry B. Omegas and dry eye: more knowledge, more questions. Optom Vis Sci. 2015;92:948–956.
   PubMed Web of Science ®Google Scholar
• Bhargava R, Kumar P, Phogat H, et al. Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye. Cont Lens Anterior Eye. 2015;38:206–210.
   PubMed Web of Science ®Google Scholar
• Pescosolido N, Giannotti R, Plateroti AM, et al. Curcumin: therapeutical potential in ophthalmology. Planta Med. 2014 Mar;80(4):249–254.
   PubMed Web of Science ®Google Scholar
• Lin X, Liu J, Chung W, et al. Polysaccharides of dendrobium officinale induce aquaporin 5 translocation by activating M3 muscarinic receptors. Planta Med. 2015;81:130–137.
   PubMed Web of Science ®Google Scholar
• Lin X, Shaw PC, Sze SC, et al. Dendrobium officinale polysaccharides ameliorate the abnormality of aquaporin 5, pro-inflammatory cytokines and inhibit apoptosis in the experimental Sjögren’s syndrome mice. Int Immunopharmacol. 2011;11:2025–2032.
   PubMed Web of Science ®Google Scholar
• Byun YS, Yoo YS, Kwon JY, et al. Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation. Exp Eye Res. 2016;143:89–97.
   PubMed Web of Science ®Google Scholar
• Rocha EM, Mantelli F, Nominato LF, et al. Hormones and dry eye syndrome: an update on what we do and don’t know. Curr Opin Ophthalmol. 2013;24:348–355.
   PubMed Web of Science ®Google Scholar
• Guzman-Aranguez A, Gasull X, Diebold Y, et al. Purinergic receptors in ocular inflammation. Mediators Inflamm. 2014;2014:320906.
   PubMed Web of Science ®Google Scholar
• Bar-Yehuda S, Luger D, Ochaion A, et al. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med. 2011;28:727–731.
   PubMed Web of Science ®Google Scholar
• Sada PR, Isenberg D, Ciurtin C. Biologic treatment in Sjögren’s syndrome. Rheumatology. 2015;54:219–230.
   PubMed Web of Science ®Google Scholar
• St Clair EW, Levesque MC, Prak ET, et al. Autoimmunity centers of excellence. Rituximab therapy for primary Sjögren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013 Apr;65(4):1097–1106.
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Seror R, et al. Efficacy and safety of belimumab given for 12 months in primary Sjögren’s syndrome: the BELISS open-label phase II study. Rheumatology (Oxford). 2015 Dec;54(12):2249–2256.
   PubMed Web of Science ®Google Scholar
• Tong L1, Petznick A, Lee S, et al. Choice of artificial tear formulation for patients with dry eye: where do we start? Cornea. 2012;31(Suppl. 1):S32–S36.
   PubMedGoogle Scholar
• Colligris B, Crooke A, Huete-Toral F, et al. An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opin Pharmacother. 2014;15:1371–1390.
   PubMed Web of Science ®Google Scholar
• Nye M, Rudner S, Bielory L. Emerging therapies in allergic conjunctivitis and dry eye syndrome. Expert Opin Pharmacother. 2013;14:1449–1465.
   PubMed Web of Science ®Google Scholar
• Hirata H, Mizerska K, Marfurt CF, et al. Hyperosmolar tears induce functional and structural alterations of corneal nerves: electrophysiological and anatomical evidence toward neurotoxicity. Invest Ophthalmol Vis Sci. 2015;56:8125–8140.
   PubMed Web of Science ®Google Scholar
• Simmons P, Liu H, Carlisle-Wilcox C, et al. Efficacy and safety of two new formulations of artificial tears in subjects with dry eye disease: a 3-month, multicenter, active-controlled, randomized trial. Clin Ophthalmol. 2015;9:665–675.
   PubMed Web of Science ®Google Scholar
• Fernandez KB, Epstein SP, Raynor GS, et al. Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution. Clin Ophthalmol. 2015;9:1137–1145.
   PubMed Web of Science ®Google Scholar
• Pinto-Bonilla JC, del Olmo-Jimeno A, Llovet-Osuna F, et al. A randomized crossover study comparing trehalose/hyaluronate eyedrops and standard treatment: patient satisfaction in the treatment of dry eye syndrome. Ther Clin Risk Management. 2015;11:595–603.
   PubMed Web of Science ®Google Scholar
• Simmons PA, Carlisle-Wilcox C, Chen R, et al. Efficacy, safety, and acceptability of a lipid-based artificial tear formulation: a randomized, controlled, multicenter clinical trial. Clin Therapeutics. 2015;37:858–868.
   PubMed Web of Science ®Google Scholar
• Pinto-Fraga J, López-Miguel A, González-García MJ, et al. Topical fluorometholone protects the ocular surface of dry eye patients from desiccating stress: a randomized controlled clinical trial. Ophthalmology. 2016;123:141–153.
   PubMed Web of Science ®Google Scholar
• Patane MA, Cohen A, From S, et al. Ocular iontophoresis of egP-437 (dexamethasone phosphate) in dry eye patients: results of a randomized clinical trial. Clin Ophthalmol. 2011;5:633–643.
   PubMedGoogle Scholar
• Liu X, Wang S, Kao AA, et al. The effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival HLA-DR expression in dry eyes. Cornea. 2012;31:1235–1239.
   PubMed Web of Science ®Google Scholar
• Yanai K, Huang J, Kadonosono K, et al. Corneal sensitivity after topical bromfenac sodium eye-drop instillation. Clin Ophthalmol. 2013;7:741–744.
   PubMedGoogle Scholar
• Hoy SM. Bromfenac ophthalmic solution 0.07%: a review of its use after cataract surgery. Clin Drug Investig. 2015;35:525–529.
   PubMed Web of Science ®Google Scholar
• Fujishima H, Fuseya M, Ogata M, et al. Efficacy of bromfenac sodium ophtlamic solution for treatment of dry eye disease. Asia Pac J Ophtalmol (Phila). 2015;4:9–13.
   PubMedGoogle Scholar
• Goldstein AL, Hannappel E, Sosne G, et al. Thymosin beta 4: a multifunctional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12:37–51.
   PubMed Web of Science ®Google Scholar
• Nassar A, Tabbara KF, Aljurf M. Ocular manifestations of graft-versus disease. Saudi J Opthalmol. 2013;27:215–222.
   PubMedGoogle Scholar
• Sosne G, Dunn SP, Thymosin KC. β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015 May;34(5):491–496.
   PubMed Web of Science ®Google Scholar
• Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13:213–225.
   PubMed Web of Science ®Google Scholar
• Semba CP, Torkildsen GL, Lonsdale JD, et al. a phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (sar 1118) for the treatment of dry eye. Am J Ophthalmol. 2012;153:1050–1060.
   PubMed Web of Science ®Google Scholar
• Zhou XQ, Wei RL. Topical cyclosporine a in the treatment of dry eye: a systematic review and meta-analysis. Cornea. 2014;33:760–767.
   PubMed Web of Science ®Google Scholar
• Agarwal P, Rupenthal ID. Modern approaches to the ocular delivery of cyclosporine. A. Drug Discov Today. 2016;21(6):977–988.
   PubMed Web of Science ®Google Scholar
• Downie LE, Keller PR. A pragmatic approach to the management of dry eye disease: evidence into practice. Optom Vis Sci. 2015;92:957–966.
   PubMed Web of Science ®Google Scholar
• Liu KC, Huynh K, Grubbs J Jr, et al. Autoimmunity in the pathogenesis and treatment of keratoconjunctivitis sicca. Curr Allergy Asthma Rep. 2014;14:403–426.
   PubMed Web of Science ®Google Scholar
• Gao J, Sana R, Calder V, et al. Mitochondrial permeability transition pore in inflammatory apoptosis of human conjunctival epithelial cells and T cells: effect of cyclosporin A. Invest Ophthalmol Vis Sci. 2013;54:4717–4733.
   PubMed Web of Science ®Google Scholar
• Zicari AM, Zicari A, Nebbioso M, et al. High-mobility group box-1 (HMGB-1) and serum soluble receptor for advanced glycation end products (sRAGE) in children affected by vernal keratoconjunctivitis. Pediatr Allergy Immunol. 2014;25:57–63.
   PubMed Web of Science ®Google Scholar
• Perez VL, Pflugfelder SC, Zhang S, et al. Lifitegrast, a novel integrin antagonist for treatment of dry eye disease. Ocular Surface. 2016;14(2):207–215.
   PubMed Web of Science ®Google Scholar
• Liew SH, Nichols KK, Klamerus KJ, et al. Tofacitinib (CP-690,550), a janus kinase inhibitor for dry eye disease results from a phase 1/2 trial. Opthalmology. 2012;119:1328–1335.
   PubMed Web of Science ®Google Scholar
• Hou J, Townson SA, Kovalchin JT, et al. Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci U S A. 2013;110:3913–3918.
   PubMed Web of Science ®Google Scholar
• Zicari AM, Nebbioso M, Zicari A, et al. Serum levels of IL-17 in patients with vernal keratoconjunctivitis. Eur Rev Med Pharmacol Sci. 2013;17:1242–1244.
   PubMed Web of Science ®Google Scholar
• Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol. 2016;100:22–27.
   PubMed Web of Science ®Google Scholar
• Alio JL, Rodriguez AE, WrobelDudzinska D. Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr Opin Ophthalmol. 2015;26:325–332.
   PubMed Web of Science ®Google Scholar
• Tseng CL, Seghatchian J, Burnouf T. Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: seeing is believing. Transfus Apher Sci. 2015;53:95–98.
   PubMed Web of Science ®Google Scholar
• Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013;7:1275–1285.
   PubMedGoogle Scholar
• Bremond-Gignac D, Gicquel JJ, Chiambaretta F. Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren’s syndrome. Expert Opin Drug Metab Toxicol. 2014;10:905–913.
   PubMed Web of Science ®Google Scholar
• Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012;130:90–100.
   PubMed Web of Science ®Google Scholar
• Schmidt TA, Sullivan DA, Knop E, et al. Transcription, translation, and function of lubricin, a boundary lubricant, at the ocular surface. JAMA Ophthalmol. 2013;13:766–776.
   Web of Science ®Google Scholar
• Samsom ML, Morrison S, Masala N, et al. Characterization of full-length recombinant human Proteoglycan 4 as an ocular surface boundary lubricant. Exp Eye Res. 2014;127:14–19.
   PubMed Web of Science ®Google Scholar
• Lambiase A, Sullivan BD, Schmidt TA, et al. A two-week, randomized, double-masked study to evaluate safety and efficacy of lubricin (150 μg/mL) eye drops versus sodium hyaluronate (HA) 0.18% eye drops (Vismed®) in patients with moderate dry eye disease. Ocul Surf. 2016 Sep 7. pii: S1542–0124(16)30096-9. doi: 10.1016/j.jtos.2016.08.004. [Epub ahead of print].
   PubMedGoogle Scholar
• Shigeyasu C, Hirano S, Akune Y, et al. Diquafosol tetrasodium increases the concentration of mucin-like substances in tears of healthy human subjects. Curr Eye Res. 2015;40(9):878–883.
   PubMed Web of Science ®Google Scholar
• Dogru M, Nakamura M, Shimazaki J, et al. Changing trends in the treatment of dry-eye disease. Expert Opin Investig Drugs. 2013;22:1581–1601.
   PubMed Web of Science ®Google Scholar